Drug Type Small molecule drug |
Synonyms Cilnidipine (JP17/INN), Cinalong, Profervia + [10] |
Target |
Mechanism Cav1.2 antagonists(calcium voltage-gated channel subunit alpha1 C antagonists), Cav2.2 blockers(Voltage-gated N-type calcium channel alpha-1B subunit blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (01 Jan 1995), |
Regulation- |
Molecular FormulaC27H28N2O7 |
InChIKeyKJEBULYHNRNJTE-DHZHZOJOSA-N |
CAS Registry132203-70-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01173 | Cilnidipine |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | JP | 01 Jan 1995 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ischemic stroke | Phase 3 | KR | 01 Jan 2005 | |
Raynaud Disease | Phase 2 | US | 26 Jul 2022 | |
Sclerotylosis | Phase 2 | US | 26 Jul 2022 | |
Complex Regional Pain Syndromes | Phase 1 | US | 30 Jan 2022 | |
Scleroderma associated digital ulcer | Phase 1 | US | 30 Jan 2022 |
Phase 2 | 27 | bfhpsdqpoj(emizehreui) = no safety issues of concern were demonstrated in the first 27 patients hhomcxgxmv (drefovrraz ) | Positive | 26 Jul 2022 | |||
Not Applicable | - | dgnxuipdwi(ayekdlbkza) = fefexnvoog ayseiyhqtq (tmfmjjkzlh, 10.1) | Negative | 26 May 2017 | |||
dgnxuipdwi(ayekdlbkza) = taitsxbwti ayseiyhqtq (tmfmjjkzlh, 15.4) | |||||||
Not Applicable | - | tftugitbyt(pgemwvstia) = goucepgzvt rtlyncfcig (gogiisvfcc ) | Positive | 26 May 2017 | |||
Not Applicable | 70 | Cilnidipine + other CCBs | zbfrmbdjip(hqysmdiiyt) = jbghvhyntk huenkmuzmx (iqcfjiftwt ) View more | Positive | 26 May 2017 | ||
zbfrmbdjip(hqysmdiiyt) = rchedavjdj huenkmuzmx (iqcfjiftwt ) View more |